PL3930715T3 - Sarakatynib do zastosowania w leczeniu idiopatycznego włóknienia płuc - Google Patents

Sarakatynib do zastosowania w leczeniu idiopatycznego włóknienia płuc

Info

Publication number
PL3930715T3
PL3930715T3 PL20710607.1T PL20710607T PL3930715T3 PL 3930715 T3 PL3930715 T3 PL 3930715T3 PL 20710607 T PL20710607 T PL 20710607T PL 3930715 T3 PL3930715 T3 PL 3930715T3
Authority
PL
Poland
Prior art keywords
saracatinib
treatment
pulmonary fibrosis
idiopathic pulmonary
idiopathic
Prior art date
Application number
PL20710607.1T
Other languages
English (en)
Inventor
Leslie COUSENS
Chad NIVENS
Katherine Jane Escott
Susan MONKLEY
Antje Prasse
Original Assignee
Astrazeneca Ab
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. filed Critical Astrazeneca Ab
Publication of PL3930715T3 publication Critical patent/PL3930715T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20710607.1T 2019-02-27 2020-02-26 Sarakatynib do zastosowania w leczeniu idiopatycznego włóknienia płuc PL3930715T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811009P 2019-02-27 2019-02-27
PCT/IB2020/051642 WO2020174420A1 (en) 2019-02-27 2020-02-26 Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor

Publications (1)

Publication Number Publication Date
PL3930715T3 true PL3930715T3 (pl) 2026-07-06

Family

ID=69784492

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20710607.1T PL3930715T3 (pl) 2019-02-27 2020-02-26 Sarakatynib do zastosowania w leczeniu idiopatycznego włóknienia płuc

Country Status (13)

Country Link
US (1) US20220117966A1 (pl)
EP (1) EP3930715B1 (pl)
JP (2) JP7547356B2 (pl)
CN (1) CN113811296B (pl)
DK (1) DK3930715T3 (pl)
ES (1) ES2994095T3 (pl)
FI (1) FI3930715T3 (pl)
HU (1) HUE067967T2 (pl)
MA (1) MA55076A (pl)
PL (1) PL3930715T3 (pl)
PT (1) PT3930715T (pl)
TW (1) TWI836022B (pl)
WO (1) WO2020174420A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112674031B (zh) * 2020-12-03 2021-11-30 同济大学 新型冠状病毒感染的啮齿动物模型的构建方法和用途
AU2022443590A1 (en) * 2022-02-28 2024-10-17 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
WO2024041633A1 (zh) * 2022-08-25 2024-02-29 广州再极医药科技有限公司 一种稠环嘧啶类化合物的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
US9844528B2 (en) * 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
US20130336889A1 (en) * 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
JP6854766B2 (ja) * 2015-01-26 2021-04-07 イエール ユニバーシティ チロシンキナーゼ阻害剤を用いる組成物および方法
ES2935361T3 (es) * 2015-04-01 2023-03-06 Istanbul Univ Rektorlugu Dasatinib para uso en el tratamiento, regresión o desaceleración del progreso de enfermedades pulmonares fibróticas
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
WO2017083789A1 (en) * 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
EP3228630A1 (en) * 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
WO2018046876A1 (en) * 2016-09-06 2018-03-15 The University Of Birmingham Treatment of chronic inflammatory disease
CN106692150B (zh) * 2016-12-21 2019-08-20 中国人民解放军第三〇二医院 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
EP3964214A1 (en) * 2020-09-02 2022-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Modulators of airway basal cells for the treatment or prevention of lung diseases

Also Published As

Publication number Publication date
JP2022521635A (ja) 2022-04-11
EP3930715A1 (en) 2022-01-05
ES2994095T3 (en) 2025-01-17
FI3930715T3 (fi) 2024-08-05
DK3930715T3 (da) 2024-08-05
WO2020174420A1 (en) 2020-09-03
TWI836022B (zh) 2024-03-21
JP7547356B2 (ja) 2024-09-09
CN113811296B (zh) 2025-05-16
US20220117966A1 (en) 2022-04-21
CN113811296A (zh) 2021-12-17
EP3930715B1 (en) 2024-05-08
JP2024174909A (ja) 2024-12-17
MA55076A (fr) 2022-04-20
TW202045180A (zh) 2020-12-16
HUE067967T2 (hu) 2024-12-28
PT3930715T (pt) 2024-08-02